000046926 000__ 01078cam\a22003855i\4500
000046926 001__ 46926
000046926 003__ SzGeWIPO
000046926 005__ 20240708150308.0
000046926 006__ m\\\\eo\\d\\\\\\\\
000046926 007__ cr bn |||m|||a
000046926 008__ 221017s2022\\\\nyu\\\\\o\\\\\000\0\eng\d
000046926 035__ $$a(OCoLC)1348117446
000046926 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000046926 041__ $$aeng
000046926 24500 $$aHow Actavis v Lilly has been applied in practice by the English courts and the issues of interpretation that have arisen under it.
000046926 264_1 $$a[New York, NY] :$$bThomson Reuters,$$c2022
000046926 300__ $$a1 online resource
000046926 336__ $$atext$$2rdacontent
000046926 337__ $$acomputer$$2rdamedia
000046926 338__ $$aonline resource$$bcr$$2rdacarrier
000046926 4901_ $$aIntellectual Property Quarterly,$$vVolume 1;
000046926 542__ $$fhttps://1.next.westlaw.com/Copyright
000046926 588__ $$aCrossref
000046926 590__ $$aPublished online: 2022
000046926 650_0 $$aIntellectual property.
000046926 650_4 $$aPharmaceuticals
000046926 650_0 $$aConsumer protection$$xLaw and legislation.
000046926 7001_ $$aBlakeney, Michael,$$eauthor.
000046926 7731_ $$tIntellectual Property Quarterly
000046926 7731_ $$wIPQUA
000046926 830_0 $$aIntellectual Property Quarterly;$$vI.P.Q. 2022, 1, 19-29
000046926 85641 $$uhttps://www.westlaw.com/Document/I8AC88310BABB11EC83A9BAB8BFCB759A/View/FullText.html?transitionType=Default&contextData=(sc.Default)&VR=3.0&RS=cblt1.0&sp=wlnintell-000$$yonline version
000046926 904__ $$aJournal article
000046926 980__ $$aIPQUA